{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:08:48Z","timestamp":1794956928057,"version":"4.9.1"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Natural Science Foundation for Young Scientists of China","award":["81502732"],"award-info":[{"award-number":["81502732"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974477"],"award-info":[{"award-number":["81974477"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830097"],"award-info":[{"award-number":["81830097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jaut.2020.102510","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T02:25:46Z","timestamp":1593570346000},"page":"102510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"special_numbering":"C","title":["The roles of PPAR\u03b3 and its agonists in autoimmune diseases: A comprehensive review"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-1048","authenticated-orcid":false,"given":"Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12016-014-8414-2","article-title":"Unmet needs in autoimmunity and potential new tools","volume":"47","author":"Lu","year":"2014","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2020.102510_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2017.03.011","article-title":"Regulatory immune cells and functions in autoimmunity and transplantation immunology","volume":"16","author":"Papp","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12016-013-8402-y","article-title":"TLR2 and TLR4 in autoimmune diseases: a comprehensive review","volume":"47","author":"Liu","year":"2014","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2020.102510_bib4","first-page":"31","article-title":"PPAR-gamma agonists as antineoplastic agents in cancers with dysregulated IGF Axis","volume":"8","author":"V","year":"2017","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.25804","article-title":"THE role of various peroxisome proliferator-activated receptors and their ligands in clinical practice","volume":"233","author":"Derosa","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jaut.2020.102510_bib6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fnins.2016.00459","article-title":"Alzheimer disease: crosstalk between the canonical wnt\/beta-catenin pathway and PPARs alpha and gamma","volume":"10","author":"Vallee","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jaut.2020.102510_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","article-title":"PPARgamma as a therapeutic target to rescue mitochondrial function in neurological disease","volume":"100","author":"Corona","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jaut.2020.102510_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","article-title":"The role and regulation of the peroxisome proliferator activated receptor alpha in human liver","volume":"136","author":"Kersten","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.jaut.2020.102510_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biochi.2016.12.008","article-title":"PPARbeta in macrophages and atherosclerosis","volume":"136","author":"Chinetti-Gbaguidi","year":"2017","journal-title":"Biochimie"},{"issue":"9","key":"10.1016\/j.jaut.2020.102510_bib10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00403-015-1571-1","article-title":"Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?","volume":"307","author":"Gupta","year":"2015","journal-title":"Arch. Dermatol. Res."},{"issue":"Supplementum 3","key":"10.1016\/j.jaut.2020.102510_bib11","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.33549\/physiolres.933439","article-title":"The role of PPARgamma in cardiovascular diseases","volume":"65","author":"Kvandova","year":"2016","journal-title":"Physiol. Res."},{"key":"10.1016\/j.jaut.2020.102510_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.redox.2017.01.023","article-title":"Redox regulation in metabolic programming and inflammation","volume":"12","author":"Griffiths","year":"2017","journal-title":"Redox biology"},{"issue":"7","key":"10.1016\/j.jaut.2020.102510_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/13543776.2012.699042","article-title":"Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present)","volume":"22","author":"Lamers","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diabet.2015.02.003","article-title":"Antidiabetic agents: potential anti-inflammatory activity beyond glucose control","volume":"41","author":"Scheen","year":"2015","journal-title":"Diabetes Metabol."},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaci.2013.05.044","article-title":"The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: from physiology to pathology","volume":"132","author":"Kiss","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10059-012-2297-y","article-title":"The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases","volume":"33","author":"Choi","year":"2012","journal-title":"Mol. Cell."},{"issue":"14","key":"10.1016\/j.jaut.2020.102510_bib17","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1021\/jm501155f","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) and ligand choreography: newcomers take the stage","volume":"58","author":"Garcia-Vallve","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jaut.2020.102510_bib18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejmech.2017.02.031","article-title":"Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: an insight into structure activity relationship","volume":"129","author":"Naim","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.jaut.2020.102510_bib19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbalip.2007.01.007","article-title":"Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators","volume":"1771","author":"Zoete","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12944-016-0404-3","article-title":"Probing the intermolecular interactions of PPARgamma-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties","volume":"16","author":"Muralikumar","year":"2017","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jaut.2020.102510_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fphar.2016.00189","article-title":"Phytochemicals mediate the expression and activity of OCTN2 as activators of the PPARgamma\/RXRalpha pathway","volume":"7","author":"Luo","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jaut.2020.102510_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications\u2013a review","volume":"13","author":"Grygiel-Gorniak","year":"2014","journal-title":"Nutr. J."},{"key":"10.1016\/j.jaut.2020.102510_bib23","doi-asserted-by":"crossref","first-page":"4810672","DOI":"10.1155\/2017\/4810672","article-title":"Deciphering the roles of thiazolidinediones and PPARgamma in bladder cancer","volume":"2017","author":"Chiu","year":"2017","journal-title":"PPAR Res."},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yexcr.2017.02.020","article-title":"Thiazolidinediones abrogate cervical cancer growth","volume":"353","author":"Wuertz","year":"2017","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1124\/mol.111.076679","article-title":"Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulators display attenuated and selective gene regulatory activity in comparison with PPARgamma full agonists","volume":"82","author":"Tan","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jaut.2020.102510_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.yrtph.2017.03.003","article-title":"Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR alpha\/gamma agonist, and its major human metabolite","volume":"86","author":"Bopst","year":"2017","journal-title":"Regul. Toxicol. Pharmacol. : RTP (Regul. Toxicol. Pharmacol.)"},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12035-014-8743-4","article-title":"Pan-PPAR modulation effectively protects APP\/PS1 mice from amyloid deposition and cognitive deficits","volume":"51","author":"Kummer","year":"2015","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib28","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2174\/1570161111311030008","article-title":"Pleiotropic effects of PPARgamma agonist on hemostatic activation in type 2 diabetes mellitus","volume":"11","author":"Ferroni","year":"2013","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.jaut.2020.102510_bib29","doi-asserted-by":"crossref","first-page":"4794576","DOI":"10.1155\/2016\/4794576","article-title":"Nutrigenomic functions of PPARs in obesogenic environments","volume":"2016","author":"Chung","year":"2016","journal-title":"PPAR Res."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jmb.2008.10.039","article-title":"Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids","volume":"385","author":"Waku","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","article-title":"Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARgamma): a review","volume":"92","author":"Wang","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.jaut.2020.102510_bib32","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.tips.2015.06.010","article-title":"Ligands for the nuclear peroxisome proliferator-activated receptor gamma","volume":"36","author":"Sauer","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.jaut.2020.102510_bib33","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jaut.2020.102510_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cbi.2017.02.014","article-title":"Antidiabetic effect of SN158 through PPARalpha\/gamma dual activation in ob\/ob mice","volume":"268","author":"Jung","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.jaut.2020.102510_bib35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.biochi.2016.10.017","article-title":"PPAR agonists, - could tissue targeting pave the way?","volume":"136","author":"Bugge","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.jaut.2020.102510_bib36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ymeth.2016.07.007","article-title":"Consumption of a high-fat, high-calorie meal is associated with an increase in intracellular co-localization of PPAR-gamma mRNA and protein in monocytes","volume":"112","author":"Henning","year":"2017","journal-title":"Methods (San Diego, Calif)"},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/apha.12665","article-title":"Peroxisome proliferator-activated receptor gamma activation favours selective subcutaneous lipid deposition by coordinately regulating lipoprotein lipase modulators, fatty acid transporters and lipogenic enzymes","volume":"217","author":"Blanchard","year":"2016","journal-title":"Acta Physiol."},{"issue":"6","key":"10.1016\/j.jaut.2020.102510_bib38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00408-007-9035-9","article-title":"The peroxisome proliferator activated receptor gamma (PPARgamma) ligand rosiglitazone modulates bronchoalveolar lavage levels of leptin, adiponectin, and inflammatory cytokines in lean and obese mice","volume":"185","author":"Holguin","year":"2007","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2010.12.008","article-title":"NF-kappaB, inflammation, and metabolic disease","volume":"13","author":"Baker","year":"2011","journal-title":"Cell Metabol."},{"issue":"5","key":"10.1016\/j.jaut.2020.102510_bib40","article-title":"Atorvastatin protects against postoperative neurocognitive disorder via a peroxisome proliferator-activated receptor-gamma signaling pathway in mice","volume":"48","author":"Y","year":"2020","journal-title":"J. Int. Med. Res."},{"issue":"7","key":"10.1016\/j.jaut.2020.102510_bib41","first-page":"21","article-title":"Pioglitazone-mediated peroxisome proliferator-activated receptor \u03b3 activation aggravates murine immune-mediated hepatitis","author":"S","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2020.102510_bib42","doi-asserted-by":"crossref","first-page":"117729","DOI":"10.1016\/j.lfs.2020.117729","article-title":"Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-\u03b2\/Smad signaling pathway","volume":"253","author":"M","year":"2020","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib43","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbrc.2017.03.106","article-title":"Activation of PPARgamma inhibits pro-inflammatory cytokines production by upregulation of miR-124 in vitro and in vivo","volume":"486","author":"Wang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cellsig.2015.12.013","article-title":"PPARgamma inhibits HMGB1 expression through upregulation of miR-142-3p in vitro and in vivo","volume":"28","author":"Yuan","year":"2016","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jaut.2020.102510_bib45","doi-asserted-by":"crossref","first-page":"e1432","DOI":"10.1038\/cddis.2014.406","article-title":"Ligand-activated peroxisome proliferator-activated receptor-\u03b4 and -\u03b3 inhibit lipopolysaccharide-primed release of high mobility group box 1 through upregulation of SIRT1","volume":"5","author":"H","year":"2014","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.jaut.2020.102510_bib46","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1084\/jem.20082771","article-title":"The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity","volume":"206","author":"Klotz","year":"2009","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib47","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/oby.21769","article-title":"PPAR-gamma agonist ameliorates liver pathology accompanied by increasing regulatory B and T cells in high-fat-diet mice","volume":"25","author":"Xu","year":"2017","journal-title":"Obesity"},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1152\/physrev.00004.2011","article-title":"Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response","volume":"92","author":"Nagy","year":"2012","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41598-017-00103-0","article-title":"Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype","volume":"7","author":"Xia","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib50","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4049\/jimmunol.1002230","article-title":"Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency","volume":"186","author":"R","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2020.102510_bib51","doi-asserted-by":"crossref","first-page":"106565","DOI":"10.1016\/j.intimp.2020.106565","article-title":"Activation of PPAR-\u03b3 induces macrophage polarization and reduces neutrophil migration mediated by heme oxygenase 1","volume":"84","author":"A","year":"2020","journal-title":"Int. Immunopharm."},{"issue":"8","key":"10.1016\/j.jaut.2020.102510_bib52","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1007\/s12035-015-9462-1","article-title":"Arctigenin suppress Th17 cells and ameliorates experimental autoimmune encephalomyelitis through AMPK and PPAR-\u03b3\/ROR-\u03b3t signaling","volume":"53","author":"L","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jaut.2020.102510_bib53","doi-asserted-by":"crossref","first-page":"104674","DOI":"10.1016\/j.psyneuen.2020.104674","article-title":"PPAR\u03b3-mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL\/6J and ob\/ob mice","volume":"117","author":"Q","year":"2020","journal-title":"Psychoneuroendocrinology"},{"issue":"9","key":"10.1016\/j.jaut.2020.102510_bib54","article-title":"Pharmacological (or synthetic) and nutritional agonists of PPAR-\u03b3 as candidates for cytokine storm modulation in COVID-19 disease","volume":"25","author":"C","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jaut.2020.102510_bib55","doi-asserted-by":"crossref","first-page":"5879090","DOI":"10.1155\/2017\/5879090","article-title":"Interactions between PPAR gamma and the canonical wnt\/beta-catenin pathway in type 2 diabetes and colon cancer","volume":"2017","author":"Lecarpentier","year":"2017","journal-title":"PPAR Res."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40169-017-0144-7","article-title":"Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT\/beta-catenin pathway","volume":"6","author":"Lecarpentier","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.jaut.2020.102510_bib57","first-page":"1","article-title":"Hypothesis of opposite interplay between the canonical WNT\/beta-catenin pathway and PPAR gamma in primary central nervous system lymphomas","volume":"31","author":"V","year":"2019","journal-title":"Curr. Issues Mol. Biol."},{"issue":"7","key":"10.1016\/j.jaut.2020.102510_bib58","article-title":"Targeting the canonical WNT\/\u03b2-Catenin pathway in cancer treatment using non-steroidal anti-inflammatory drugs","volume":"8","author":"V","year":"2019","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.jaut.2020.102510_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/all.13182","article-title":"Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review","volume":"72","author":"Kolkhir","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaut.2020.102510_bib60","first-page":"396","article-title":"The emerging role of epigenetics in autoimmune thyroid diseases","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102510_bib61","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1089\/105072503322401032","article-title":"Peroxisome proliferator-activated receptor-gamma gene expression in orbital adipose\/connective tissues is increased during the active stage of Graves' ophthalmopathy","volume":"13","author":"Mimura","year":"2003","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"issue":"4","key":"10.1016\/j.jaut.2020.102510_bib62","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1167\/iovs.15-18018","article-title":"Celecoxib and pioglitazone as potential therapeutics for regulating TGF-beta-induced hyaluronan in dysthyroid myopathy","volume":"57","author":"Cheng","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.jaut.2020.102510_bib63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1507\/endocrj.EJ19-0521","article-title":"Anti-oxidative and anti-adipogenic effects of caffeine in an in vitro model of Graves' orbitopathy","volume":"67","author":"K","year":"2020","journal-title":"Endocr. J."},{"issue":"6","key":"10.1016\/j.jaut.2020.102510_bib64","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/17512433.2016.1157468","article-title":"Novel therapies for thyroid autoimmune diseases","volume":"9","author":"Fallahi","year":"2016","journal-title":"Expet Rev. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102510_bib65","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1089\/thy.2015.0625","article-title":"Pioglitazone, a PPARgamma agonist, upregulates the expression of caveolin-1 and catalase, essential for thyroid cell homeostasis: a clue to the pathogenesis of hashimoto's thyroiditis","volume":"26","author":"Werion","year":"2016","journal-title":"Thyroid : official journal of the American Thyroid Association"},{"issue":"7","key":"10.1016\/j.jaut.2020.102510_bib66","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.autrev.2019.05.004","article-title":"Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy","volume":"18","author":"F","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.jaut.2020.102510_bib67","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.imbio.2012.08.267","article-title":"Interferon-\u03b1, -\u03b2 and -\u03b3 induce CXCL11 secretion in human thyrocytes: modulation by peroxisome proliferator-activated receptor \u03b3 agonists","volume":"218","author":"A","year":"2013","journal-title":"Immunobiology"},{"issue":"12","key":"10.1016\/j.jaut.2020.102510_bib68","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.4049\/jimmunol.164.12.6503","article-title":"Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells","volume":"164","author":"M","year":"2000","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.jaut.2020.102510_bib69","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41423-018-0198-5","article-title":"CD70 defines a subset of proinflammatory and CNS-pathogenic T1\/T17 lymphocytes and is overexpressed in multiple sclerosis","volume":"16","author":"D","year":"2019","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/cmi.2014.47","article-title":"Association between vitamin D receptor polymorphisms and multiple sclerosis: systematic review and meta-analysis of case-control studies","volume":"12","author":"T","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102510_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041212","article-title":"Demyelination in multiple sclerosis: reprogramming energy metabolism and potential PPARgamma agonist treatment approaches","volume":"19","author":"Vallee","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.gene.6363832","article-title":"Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation","volume":"3","author":"Natarajan","year":"2002","journal-title":"Gene Immun."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib73","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nn.2702","article-title":"Retinoid X receptor gamma signaling accelerates CNS remyelination","volume":"14","author":"Huang","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jaut.2020.102510_bib74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.fitote.2015.08.001","article-title":"An overview on neuroprotective effects of isothiocyanates for the treatment of neurodegenerative diseases","volume":"106","author":"Giacoppo","year":"2015","journal-title":"Fitoterapia"},{"key":"10.1016\/j.jaut.2020.102510_bib75","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.fitote.2014.03.018","article-title":"Antiinflammatory activity of glucomoringin isothiocyanate in a mouse model of experimental autoimmune encephalomyelitis","volume":"95","author":"Galuppo","year":"2014","journal-title":"Fitoterapia"},{"key":"10.1016\/j.jaut.2020.102510_bib76","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.2147\/DDDT.S110514","article-title":"Moringin activates Wnt canonical pathway by inhibiting GSK3beta in a mouse model of experimental autoimmune encephalomyelitis","volume":"10","author":"Giacoppo","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"issue":"16","key":"10.1016\/j.jaut.2020.102510_bib77","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1073\/pnas.2000208117","article-title":"A dual effect of ursolic acid to the treatment of multiple sclerosis through both immunomodulation and direct remyelination","volume":"117","author":"Z","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib78","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jn\/136.3.700","article-title":"Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis","volume":"136","author":"Racke","year":"2006","journal-title":"J. Nutr."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib79","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1189\/jlb.0803402","article-title":"Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients","volume":"75","author":"S","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jaut.2020.102510_bib80","doi-asserted-by":"crossref","first-page":"627463","DOI":"10.1155\/2008\/627463","article-title":"PPAR-gamma: therapeutic potential for multiple sclerosis","volume":"2008","author":"D","year":"2008","journal-title":"PPAR Res."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib81","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.4049\/jimmunol.178.3.1904","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonists suppress the production of IL-12 family cytokines by activated glia","volume":"178","author":"Xu","year":"2007","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2020.102510_bib82","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamaneurol.2015.4807","article-title":"Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis","volume":"73","author":"N","year":"2016","journal-title":"JAMA neurology"},{"issue":"10055","key":"10.1016\/j.jaut.2020.102510_bib83","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2020.102510_bib84","doi-asserted-by":"crossref","first-page":"55384","DOI":"10.18632\/oncotarget.19526","article-title":"Ginsenoside Rg1 attenuates adjuvant-induced arthritis in rats via modulation of PPAR-\u03b3\/NF-\u03baB signal pathway","author":"Leiming Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jaut.2020.102510_bib85","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/1529-0131(200011)43:11<2531::AID-ANR21>3.0.CO;2-V","article-title":"Modulation of fibroblast-mediated cartilage degradation by articular chondrocytes in rheumatoid arthritis","volume":"43","author":"Pap","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2020.102510_bib86","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000441","article-title":"The peroxisome proliferator activated receptor-gamma pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis","volume":"2","author":"Marder","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib87","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1038\/s41598-017-12570-6","article-title":"Functional role of PPAR-gamma on the proliferation and migration of fibroblast-like synoviocytes in rheumatoid arthritis","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2020.102510_bib88","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2249.2002.01876.x","article-title":"Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor \u03b3 mediated signalling pathway","volume":"129","author":"Amasaki","year":"2002","journal-title":"Clin. Exp. Immunol."},{"issue":"7","key":"10.1016\/j.jaut.2020.102510_bib89","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/art.23600","article-title":"Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms","volume":"58","author":"Chung","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"7-8","key":"10.1016\/j.jaut.2020.102510_bib90","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clinbiochem.2010.01.012","article-title":"Insulin resistance in early untreated rheumatoid arthritis patients","volume":"43","author":"Shahin","year":"2010","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jaut.2020.102510_bib91","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/ar4290","article-title":"Peroxisome proliferator-activated receptor \u03b3 agonist effect on rheumatoid arthritis: a randomized controlled trial","volume":"15","author":"Ormseth","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2020.102510_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CMAMD.S5951","article-title":"Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study)","volume":"4","author":"Shahin","year":"2011","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"issue":"12","key":"10.1016\/j.jaut.2020.102510_bib93","first-page":"2388","article-title":"Increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis","volume":"34","author":"Avalos","year":"2007","journal-title":"J. Rheumatol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102510_bib94","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/art.38686","article-title":"Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor gamma agonist therapy","volume":"66","author":"Ormseth","year":"2014","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2020.102510_bib95","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2147\/DDDT.S206695","article-title":"15-Deoxy-\u0394-prostaglandin J as a potential regulator of bone metabolism via PPAR\u03b3-dependent and independent pathways: a review","volume":"13","author":"X","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jaut.2020.102510_bib96","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.gene.2019.01.048","article-title":"The effect of ginger supplementation on some immunity and inflammation intermediate genes expression in patients with active Rheumatoid Arthritis","volume":"698","author":"A","year":"2019","journal-title":"Gene"},{"issue":"21","key":"10.1016\/j.jaut.2020.102510_bib97","doi-asserted-by":"crossref","first-page":"e1800202","DOI":"10.1002\/mnfr.201800202","article-title":"Morin exerts anti-arthritic effects by attenuating synovial angiogenesis via activation of peroxisome proliferator activated receptor-\u03b3","volume":"62","author":"Y","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib98","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12016-016-8552-9","article-title":"Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis","volume":"52","author":"Maria","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.jaut.2020.102510_bib99","doi-asserted-by":"crossref","first-page":"88","DOI":"10.12688\/f1000research.10022.1","article-title":"Recent advances in managing systemic sclerosis","volume":"6","author":"Aringer","year":"2017","journal-title":"F1000Research"},{"issue":"5","key":"10.1016\/j.jaut.2020.102510_bib100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2010.09.015","article-title":"Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy","volume":"10","author":"Wei","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2020.102510_bib101","doi-asserted-by":"crossref","first-page":"124624","DOI":"10.1155\/2015\/124624","article-title":"The role of PPAR gamma in systemic sclerosis","volume":"2015","author":"Dantas","year":"2015","journal-title":"PPAR Res."},{"issue":"4","key":"10.1016\/j.jaut.2020.102510_bib102","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.20104","article-title":"Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma","volume":"50","author":"Ghosh","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib103","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopha.2005.04.004","article-title":"Inhibition of skin sclerosis by 15deoxy delta12,14-prostaglandin J2 and retrovirally transfected prostaglandin D synthase in a mouse model of bleomycin-induced scleroderma","volume":"60","author":"Kohno","year":"2006","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib104","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2353\/ajpath.2009.080574","article-title":"Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma","volume":"174","author":"Wu","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102510_bib105","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/art.24761","article-title":"Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis","volume":"60","author":"Kapoor","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib106","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13075-018-1630-z","article-title":"Adipocyte-specific repression of PPAR-gamma by NCoR contributes to scleroderma skin fibrosis","volume":"20","author":"K","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.jaut.2020.102510_bib107","doi-asserted-by":"crossref","first-page":"e13778","DOI":"10.1371\/journal.pone.0013778","article-title":"PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis","volume":"5","author":"Wei","year":"2010","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2133.2012.11199.x","article-title":"Peroxisome proliferator-activated receptor gamma agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts","volume":"168","author":"Antonelli","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jaut.2020.102510_bib109","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fphar.2017.00174","article-title":"Deficient adipogenesis of scleroderma patient and healthy african American monocytes","volume":"8","author":"Lee","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jaut.2020.102510_bib110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/1874312901206010103","article-title":"Regulation of matrix remodeling by peroxisome proliferator-activated receptor-gamma: a novel link between metabolism and fibrogenesis","volume":"6","author":"Wei","year":"2012","journal-title":"Open Rheumatol. J."},{"issue":"10","key":"10.1016\/j.jaut.2020.102510_bib111","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.RES.0000073585.50092.14","article-title":"Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth","volume":"92","author":"Ameshima","year":"2003","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.jaut.2020.102510_bib112","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1172\/JCI32503","article-title":"An antiproliferative BMP-2\/PPAR\u03b3\/apoE axis in human and murine SMCs and its role in pulmonary hypertension","volume":"118","author":"Hansmann","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib113","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/ar4432","article-title":"A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility","volume":"16","author":"Lopez-Isac","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2020.102510_bib114","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-015-0641-2","article-title":"A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-gamma) gene and systemic sclerosis","volume":"17","author":"Marangoni","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.jaut.2020.102510_bib115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/BOR.0b013e32833de1a7","article-title":"Peroxisome proliferator-activated receptor gamma: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis","volume":"22","author":"Wei","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.jaut.2020.102510_bib116","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bcp.2019.02.029","article-title":"Cannabinoid derivatives acting as dual PPAR\u03b3\/CB2 agonists as therapeutic agents for systemic sclerosis","volume":"163","author":"G-M","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102510_bib117","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","article-title":"Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis","volume":"71","author":"Gonzalez","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib118","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12931-016-0373-0","article-title":"Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung","volume":"17","author":"Lucattelli","year":"2016","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.jaut.2020.102510_bib119","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/annrheumdis-2012-202716","article-title":"A synthetic PPAR-gamma agonist triterpenoid ameliorates experimental fibrosis: PPAR-gamma-independent suppression of fibrotic responses","volume":"73","author":"Wei","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.jaut.2020.102510_bib120","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1136\/annrheumdis-2015-208029","article-title":"Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis","volume":"75","author":"Ruzehaji","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"undefined","key":"10.1016\/j.jaut.2020.102510_bib121","first-page":"1512","article-title":"The therapeutic and pathogenic role of autophagy in autoimmune diseases","volume":"9","author":"Y","year":"2018","journal-title":"Front. Immunol."},{"issue":"undefined","key":"10.1016\/j.jaut.2020.102510_bib122","first-page":"1","article-title":"A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus","volume":"93","author":"L","year":"2018","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib123","article-title":"Tumour necrosis factor inhibitor exposure and radiographic outcomes in Veterans with rheumatoid arthritis: a longitudinal cohort study","volume":"3","author":"Cannon","year":"2019","journal-title":"Rheumatol Adv Pract"},{"issue":"6","key":"10.1016\/j.jaut.2020.102510_bib124","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/0961203310392419","article-title":"PPAR\u03b3 expression is increased in systemic lupus erythematosus patients and represses CD40\/CD40L signaling pathway","volume":"20","author":"O","year":"2011","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib125","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/imm.12256","article-title":"Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus","volume":"142","author":"Aprahamian","year":"2014","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib126","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clim.2013.07.002","article-title":"The peroxisome-proliferator activated receptor-gamma agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus","volume":"149","author":"Zhao","year":"2013","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib127","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4049\/jimmunol.182.1.340","article-title":"The peroxisome proliferator-activated receptor \u03b3 agonist rosiglitazone ameliorates murine lupus by induction of adiponectin","volume":"182","author":"Aprahamian","year":"2009","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102510_bib128","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/imm.12806","article-title":"Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype","volume":"152","author":"Obreque","year":"2017","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.jaut.2020.102510_bib129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1017\/S0007114518001976","article-title":"Virgin olive oil and its phenol fraction modulate monocyte\/macrophage functionality: a potential therapeutic strategy in the treatment of systemic lupus erythematosus","volume":"120","author":"A-S","year":"2018","journal-title":"Br. J. Nutr."},{"issue":"12","key":"10.1016\/j.jaut.2020.102510_bib130","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1177\/0961203317701842","article-title":"Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone","volume":"26","author":"M","year":"2017","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib131","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12967-020-02289-w","article-title":"Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases","volume":"18","author":"Z","year":"2020","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.jaut.2020.102510_bib132","article-title":"Environmental factors in the pathogenesis of primary Sj\u00f6gren\u2019s syndrome","volume":"287","author":"B","year":"2020","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jaut.2020.102510_bib133","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/TACG.S193969","article-title":"Sjogren-larsson syndrome: mechanisms and management","volume":"13","author":"B","year":"2020","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.jaut.2020.102510_bib134","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaut.2017.09.007","article-title":"Impaired anti-inflammatory activity of PPAR\u03b3 in the salivary epithelia of Sj\u00f6gren's syndrome patients imposed by intrinsic NF-\u03baB activation","volume":"86","author":"V","year":"2018","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.jaut.2020.102510_bib135","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/108076803322660495","article-title":"Peroxisome proliferator-activated receptor agonists inhibit interleukin-1beta-mediated nitric oxide production in cultured lacrimal gland acinar cells","volume":"19","author":"B","year":"2003","journal-title":"J. Ocul. Pharmacol. Therapeut. : the official journal of the Association for Ocular Pharmacology and Therapeutics"},{"issue":"8","key":"10.1016\/j.jaut.2020.102510_bib136","first-page":"4886","article-title":"Anti-inflammatory effect of peroxisome proliferator-activated receptor-\u03b3 (PPAR-\u03b3) on non-obese diabetic mice with Sjogren's syndrome","volume":"7","author":"L","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.jaut.2020.102510_bib137","doi-asserted-by":"crossref","first-page":"102335","DOI":"10.1016\/j.jaut.2019.102335","article-title":"Autoimmune epithelitis (Sj\u00f6gren's syndrome); the impact of metabolic status of glandular epithelial cells on auto-immunogenicity","volume":"104","author":"Katsiougiannis","year":"2019","journal-title":"J. Autoimmun."},{"issue":"10003","key":"10.1016\/j.jaut.2020.102510_bib138","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"C","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jaut.2020.102510_bib139","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12016-014-8427-x","article-title":"Extrahepatic autoimmune conditions associated with primary biliary cirrhosis","volume":"48","author":"F","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00795-013-0017-0","article-title":"PPAR\u03b3 ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis","volume":"46","author":"N","year":"2013","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.jaut.2020.102510_bib141","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","article-title":"PPAR\u03b3 as a therapeutic target to rescue mitochondrial function in neurological disease","volume":"100","author":"Corona","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jaut.2020.102510_bib142","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jaut.2020.102510_bib143","first-page":"1","article-title":"Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study)","volume":"4","author":"S","year":"2011","journal-title":"Clin. Med. Insights Arthritis Musculoskelet. Disord."},{"issue":"9","key":"10.1016\/j.jaut.2020.102510_bib144","first-page":"2331","article-title":"Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor \u03b3 agonist therapy","volume":"66","author":"O","year":"2014","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"5","key":"10.1016\/j.jaut.2020.102510_bib145","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/ar4290","article-title":"Peroxisome proliferator-activated receptor \u03b3 agonist effect on rheumatoid arthritis: a randomized controlled trial","volume":"15","author":"O","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib146","doi-asserted-by":"crossref","first-page":"64","DOI":"10.7812\/TPP\/09-052","article-title":"Thiazolidinediones: a 2010 perspective","volume":"14","author":"Krishnaswami","year":"2010","journal-title":"Perm. J."},{"key":"10.1016\/j.jaut.2020.102510_bib147","doi-asserted-by":"crossref","first-page":"7242030","DOI":"10.1155\/2019\/7242030","article-title":"15-Deoxy\u2013(12,14)-Prostaglandin J2 (15d-PGJ2), an endogenous ligand of PPAR-gamma: function and mechanism","volume":"2019","author":"Li","year":"2019","journal-title":"PPAR Res."},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib148","doi-asserted-by":"crossref","first-page":"191","DOI":"10.31768\/2312-8852.2016.38(3):191-194","article-title":"The effect of \u03c9-fatty acids on mRNA expression level of PPAR\u03b3 in patients with gastric adenocarcinoma","volume":"38","author":"A H","year":"2016","journal-title":"Exp. Oncol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102510_bib149","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.intimp.2014.09.009","article-title":"The role of nitrated fatty acids and peroxisome proliferator-activated receptor gamma in modulating inflammation","volume":"23","author":"N","year":"2014","journal-title":"Int. Immunopharm."},{"issue":"101376","key":"10.1016\/j.jaut.2020.102510_bib150","article-title":"A FABP4-PPAR\u03b3 signaling axis regulates human monocyte responses to electrophilic fatty acid nitroalkenes","volume":"29","author":"Lamas Bervejillo","year":"2020","journal-title":"Redox Biol"},{"issue":"3","key":"10.1016\/j.jaut.2020.102510_bib151","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pan.2017.02.016","article-title":"Oxidized phospholipids exert a dual effect on bile acid-induced CCL2 expression in pancreatic acini","volume":"17","author":"Mateu","year":"2017","journal-title":"Pancreatology"},{"issue":"11","key":"10.1016\/j.jaut.2020.102510_bib152","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.neurobiolaging.2005.09.038","article-title":"Amyloid beta peptide as a physiological modulator of neuronal 'A'-type K+ current","volume":"27","author":"Plant","year":"2006","journal-title":"Neurobiol. Aging"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120301323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120301323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:26:16Z","timestamp":1760257576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841120301323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":152,"alternative-id":["S0896841120301323"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102510","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The roles of PPAR\u03b3 and its agonists in autoimmune diseases: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102510"}}